Mindset BioPharmaceuticals announced that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss. The notice indicates that a patent application has been allowed.

Insulin sensitizer drugs include Rosiglitazone and Pioglitazone which have been approved for the treatment of type II diabetes mellitus.

Dr. Daniel Chain, Mindset founder & president and co-inventor of the patent, said: “We are gratified that our seminal ideas concerning the ability of this class of drugs to combat Senile Dementia and other types of memory loss are being tested by GlaxoSmithKline, a major pharmaceutical company.”

Mindset is a privately held company focused on memory loss in Alzheimer’s disease, Senile Dementia, Dementia and Age-Related Cognitive Impairment. Mindset has two wholly-owned subsidiaries: Mindset BioPharmaceuticals Israel collaborated with Proteome Sciences Plc on project Pro-Tamad to discover and patent proteins which may be used to develop tests for the early diagnosis and treatment of Alzheimer’s disease; MindGenix is a contract research organization that provides testing in a preclinical model of Alzheimer’s disease and related disorders.